{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:37:38Z","timestamp":1791859058328,"version":"4.3.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T00:00:00Z","timestamp":1540857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T00:00:00Z","timestamp":1540857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GW Research Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s40263-018-0578-5","type":"journal-article","created":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T20:52:18Z","timestamp":1540846338000},"page":"1053-1067","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":443,"title":["A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects"],"prefix":"10.1007","volume":"32","author":[{"given":"Lesley","family":"Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Gidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Blakey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bola","family":"Tayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilmour","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,30]]},"reference":[{"issue":"21","key":"578_CR1","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","volume":"376","author":"O Devinsky","year":"2017","unstructured":"Devinsky O, Cross JH, Laux L, et al. Cannabidiol in Dravet Syndrome Study Group. Trial of Cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011\u201320.","journal-title":"N Engl J Med"},{"issue":"14","key":"578_CR2","doi-asserted-by":"publisher","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","volume":"90","author":"O Devinsky","year":"2018","unstructured":"Devinsky O, Patel AD, Thiele EA, et al. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90(14):e1204\u201311.","journal-title":"Neurology"},{"issue":"20","key":"578_CR3","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","volume":"378","author":"O Devinsky","year":"2018","unstructured":"Devinsky O, Patel AD, Cross JH, et al. Effect of cannabidiol on drop seizures in the Lennox\u2013Gastaut syndrome. N Engl J Med. 2018;378(20):1888\u201397.","journal-title":"N Engl J Med"},{"issue":"10125","key":"578_CR4","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","volume":"391","author":"EA Thiele","year":"2018","unstructured":"Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085\u201396.","journal-title":"Lancet"},{"issue":"4","key":"578_CR5","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s13311-015-0377-3","volume":"12","author":"C Ibeas Bih","year":"2015","unstructured":"Ibeas Bih C, Chen T, Nunn AV, Bazelot M, Dallas M, Whalley BJ. Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015;12(4):699\u2013730.","journal-title":"Neurotherapeutics."},{"issue":"11","key":"578_CR6","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1210\/me.2011-1197","volume":"25","author":"CM Henstridge","year":"2011","unstructured":"Henstridge CM, Balenga NA, Kargl J, et al. Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55. Mol Endocrinol. 2011;25(11):1835\u201348.","journal-title":"Mol Endocrinol"},{"issue":"13","key":"578_CR7","doi-asserted-by":"publisher","first-page":"5193","DOI":"10.1073\/pnas.1211204110","volume":"110","author":"S Sylantyev","year":"2013","unstructured":"Sylantyev S, Jensen TP, Ross RA, Rusakov DA. Cannabinoid and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses. Proc Natl Acad Sci USA. 2013;110(13):5193\u20138.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"3","key":"578_CR8","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/bph.12944","volume":"172","author":"JM McPartland","year":"2015","unstructured":"McPartland JM, Duncan M, Di Marzo V, Pertwee RG. Are cannabidiol and \u0394(9)-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol. 2015;172(3):737\u201353.","journal-title":"Br J Pharmacol."},{"issue":"5\u20136","key":"578_CR9","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.lfs.2011.05.018","volume":"89","author":"R Jiang","year":"2011","unstructured":"Jiang R, Yamaori S, Takeda S, Yamamoto I, Watanabe K. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci. 2011;89(5\u20136):165\u201370.","journal-title":"Life Sci"},{"issue":"3","key":"578_CR10","doi-asserted-by":"publisher","first-page":"206","DOI":"10.2174\/1389200217666151210142051","volume":"17","author":"O Zendulka","year":"2016","unstructured":"Zendulka O, Dovrt\u011blov\u00e1 G, Noskov\u00e1 K, et al. Cannabinoids and cytochrome P450 interactions. Curr Drug Metab. 2016;17(3):206\u201326.","journal-title":"Curr Drug Metab"},{"issue":"7","key":"578_CR11","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1124\/dmd.109.026898","volume":"37","author":"A Mazur","year":"2009","unstructured":"Mazur A, Lichti CF, Prather PL, et al. Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metab Dispos. 2009;37(7):1496\u2013504.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"578_CR12","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/03602532.2013.849268","volume":"46","author":"SM Stout","year":"2014","unstructured":"Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014;46(1):86\u201395.","journal-title":"Drug Metab Rev"},{"issue":"8","key":"578_CR13","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/epi.13060","volume":"56","author":"AL Geffrey","year":"2015","unstructured":"Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56(8):1246\u201351.","journal-title":"Epilepsia."},{"issue":"9","key":"578_CR14","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1111\/epi.13852","volume":"58","author":"TE Gaston","year":"2017","unstructured":"Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP. UAB CBD Program. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017;58(9):1586\u201392.","journal-title":"Epilepsia."},{"issue":"10","key":"578_CR15","first-page":"485","volume":"56","author":"AW Zuardi","year":"1995","unstructured":"Zuardi AW, Morais SL, Guimar\u00e3es FS, Mechoulam R. Antipsychotic effect of cannabidiol. J Clin Psychiatry. 1995;56(10):485\u20136.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"578_CR16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2174\/157488611798280924","volume":"6","author":"MM Bergamaschi","year":"2011","unstructured":"Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa JA. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf. 2011;6(4):237\u201349.","journal-title":"Curr Drug Saf."},{"issue":"10","key":"578_CR17","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1111\/epi.13499","volume":"57","author":"EJ Hess","year":"2016","unstructured":"Hess EJ, Moody KA, Geffrey AL, et al. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia. 2016;57(10):1617\u201324.","journal-title":"Epilepsia."},{"key":"578_CR18","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","volume":"15","author":"O Devinsky","year":"2016","unstructured":"Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment resistant epilepsy: an open-label interventional trial. The Lancet Neurology. 2016;15:270\u20138.","journal-title":"The Lancet Neurology"},{"key":"578_CR19","unstructured":"Whalley BJ, Stott C, Gray RA. The human metabolite of cannabidiol, 7-hydroxy-cannabidiol, but not 7-carboxy-cannabidiol, is anticonvulsant in the maximal electroshock threshold test (MEST) in mouse [abstract no. 1.435]. AES Conference; 2017."},{"issue":"8","key":"578_CR20","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/j.1552-4604.1995.tb04117.x","volume":"35","author":"H Boxenbaum","year":"1995","unstructured":"Boxenbaum H, Battle M. Effective half-life in clinical pharmacology. J Clin Pharmacol. 1995;35(8):763\u20136.","journal-title":"J Clin Pharmacol"},{"key":"578_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.eplepsyres.2016.10.020","volume":"129","author":"BE Gidal","year":"2017","unstructured":"Gidal BE, Clark AM, Anders B, Gilliam F. The application of half-life in clinical decision making: comparison of the pharmacokinetics of extended-release topiramate (USL255) and immediate-release topiramate. Epilepsy Res. 2017;129:26\u201332.","journal-title":"Epilepsy Res"},{"issue":"8","key":"578_CR22","doi-asserted-by":"publisher","first-page":"14451","DOI":"10.3390\/molecules200814451","volume":"20","author":"E Moghimipour","year":"2015","unstructured":"Moghimipour E, Ameri A, Handali S. Absorption-enhancing effects of bile salts. Molecules. 2015;20(8):14451\u201373.","journal-title":"Molecules"}],"updated-by":[{"DOI":"10.1007\/s40263-019-00617-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T00:00:00Z","timestamp":1551657600000}}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-018-0578-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0578-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0578-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T05:22:37Z","timestamp":1606368157000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-018-0578-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,30]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["578"],"URL":"https:\/\/doi.org\/10.1007\/s40263-018-0578-5","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,30]]},"assertion":[{"value":"30 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2019","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Page 1065, Discussion, Single and Multiple Dose CBD PK, column 2 - the equation that read:","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This trial was funded by GW Research Ltd. The open-access fee was paid by Greenwich Biosciences, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Lesley Taylor, Gilmour Morrison and Bola Tayo are employed by GW Research Ltd and have shares in the company. Graham Blakey and Barry Gidal have received consultancy fees from GW Research Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This trial was conducted in accordance with International Conference on Harmonisation Good Clinical Practice guidelines and ethical principles that have their origin in the Declaration of Helsinki. Protocols were approved by an Independent Ethics Committee (Foundation Evaluation of Ethics in Biomedical Research, Assen, The Netherlands) before eligibility screening.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research Involving Human Participants"}},{"value":"Written informed consent was obtained from each subject before any trial-related procedures were performed.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}